3Deres K, Scbroder CH, Paessens A, et al. Interfering with capsid formation:a practicable antiviral strategy against hepatitis B virus[J] ? Hepatology, 2004, 39(3): 838-840.
4Deres K, Scbroder CH, Paessens A, et al. Inhibition of hepatitis B virus replication by drug induced depletion of nucleocapsides[J]. Science, 2003, 299(5608): 893-896.
5Stray SJ, Zlomick A. BAY 41-4109 has multiple effects on hepatitis B virus capsid assembly[J]. J Mol Recognit, 2006, 19(6):542-548.
6Wu GY, Zheng XJ, Yin CC, et al. Inhibition of hepatitis B virus replication by Bay 41-4109 and its association with nucleocapsid disas sembly[J]. J Chemother, 2008, 20(4): 458-467.
7Weber O, Schlemmer KH, Hartmann E, et al. Inhibition of human hepatitis B virus (HBV) by a novel non-nucleosidic compound in a transgenic mouse model[J]. Antiviral Res, 2002, 54(2): 69-78.
8Morrey JD, Bailey KW, Korba BE, et al. Utilization of transgenic mice replieating high levels of hepatitis B virus for antiviral evaluation of lamivudine[J]. Antiviral Res, 1999, 42(2): 97-108.
9SEIFER M,PATTY A,FARAJ A,et al.In vitro studies on the mechanism of action of L-nucleoside inhibitors of hepatitis B virus replication reveal differences between LdT and lamivudine[J].Hepatology,2001,34(S1):635A.
10KIM JW,PARK SH,LOUIE SG.Telbivudine:a novel nucleoside analog for chronic hepatitis B[J].Ann Pharmacother,2006,40 (3):472-478.
